Strong growth in resilient market
- Revenue increased by 21 per cent to EUR 81.3m (67.0) with organic growth of 14 per cent
- Operating profit (EBIT) increased by 28 per cent to EUR 10.1m (7.9) at a margin of 12.5 per cent (11.8). Profit for the quarter totalled EUR 3.2m (10.0)
- Adjusted EBITA increased by 15 per cent to EUR 20.3m (17.7) at a margin of 25.0 per cent (26.4) with items affecting comparability of EUR -4.3m (-5.7)
- Earnings per share before and after dilution EUR 0.01 (0.03). Earnings per share adjusted for non-recurring items EUR 0.02
"Vimian delivers another quarter with strong organic growth of 14 per cent and positive momentum across all segments. We are well positioned leveraging strong global market positions in attractive niches of the animal health market. The sector remains resilient as consumers continue to prioritise spending on more and better healthcare for their pets", says Dr. Fredrik Ullman, CEO of Vimian Group and continues:
"The adjusted EBITA margin of 25 per cent reflects the mix effect in Specialty Pharma where US Specialised Nutrition delivers exceptional growth, alongside our investments to drive growth. We are consistently striving to improve performance and aim to deliver margin expansion during the second half of the year."
Last twelve months pro-forma revenues (including the full year impact of all acquisitions completed during the twelve months ending 30 June) reached EUR 329 million and pro-forma adjusted EBITA EUR 85.7 million.
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=2001156
To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q2-2023
Related presentation materials will be available on Vimian's website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, has 1,000 employees and annual revenues of approximately EUR 280 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.
This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-17 07:45 CEST.
